Drug Discovery News ∙ 11/09/2022 ∙ Division of Preclinical Innovation
Drug combinations have emerged as the standards of care for difficult-to-treat conditions including for cancers and infectious diseases. “Once our drugs are targeting parallel pathways, we can overcome resistance mechanisms in a multitude of ways,” said Craig Thomas, a drug discovery chemist at NCATS. The activities of individual drugs can add up when they attack a disease from multiple directions. And drug combinations may show potent synergistic responses that are greater than the sum of their parts, potentially enabling a lower effective dose and a larger therapeutic index.